

Julie Delyon

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4577335/publications.pdf>

Version: 2024-02-01

70
papers

1,411
citations

394421

19
h-index

377865

34
g-index

95
all docs

95
docs citations

95
times ranked

2374
citing authors

#	ARTICLE	IF	CITATIONS
1	Clinicopathologic and molecular characterization of melanomas mutated for CTNNB1 and MAPK. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2022, 480, 475-480.	2.8	6
2	PD-1 blockade with pembrolizumab in classic or endemic Kaposi's sarcoma: a multicentre, single-arm, phase 2 study. Lancet Oncology, The, 2022, 23, 491-500.	10.7	20
3	Yield of FDG PET/CT for Defining the Extent of Disease in Patients with Kaposi Sarcoma. Cancers, 2022, 14, 2189.	3.7	4
4	IL-6 blockade in cancer patients treated with immune checkpoint blockade: A win-win strategy. Cancer Cell, 2022, 40, 450-451.	16.8	8
5	18FDG PET Assessment of Therapeutic Response in Patients with Advanced or Metastatic Melanoma Treated with First-Line Immune Checkpoint Inhibitors. Cancers, 2022, 14, 3190.	3.7	5
6	Managing immune checkpoint inhibition in transplant recipients. Lancet Oncology, The, 2022, 23, 969-971.	10.7	2
7	Severe immune-related hepatitis induced by immune checkpoint inhibitors: Clinical features and management proposal. Clinics and Research in Hepatology and Gastroenterology, 2021, 45, 101491.	1.5	18
8	Clinical response to immune checkpoint inhibition in patients with advanced skin cancers receiving concurrent ruxolitinib therapy for haematological malignancy. British Journal of Dermatology, 2021, 184, 564-566.	1.5	1
9	Treatment strategies and safety of rechallenge in the setting of immune checkpoint inhibitors-related myositis: a national multicentre study. Rheumatology, 2021, 60, 5753-5764.	1.9	17
10	A Multicenter Phase II Study of Pazopanib in Patients with Unresectable Dermatofibrosarcoma Protuberans. Journal of Investigative Dermatology, 2021, 141, 761-769.e2.	0.7	7
11	Late-onset and long-lasting immune-related adverse events from immune checkpoint-inhibitors: An overlooked aspect in immunotherapy. European Journal of Cancer, 2021, 149, 153-164.	2.8	79
12	Dabrafenib and trametinib exposure-efficacy and tolerance in metastatic melanoma patients: a pharmacokineticâ€“pharmacodynamic real-life study. Cancer Chemotherapy and Pharmacology, 2021, 88, 427-437.	2.3	5
13	Phase II Open-Label Multicenter Study of Palbociclib + Vemurafenib in BRAF</i>V600MUT Metastatic Melanoma Patients: Uncovering CHEK2 as a Major Response Mechanism. Clinical Cancer Research, 2021, 27, 3876-3883.	7.0	8
14	Long-Term Outcome of Neoadjuvant Tyrosine Kinase Inhibitors Followed by Complete Surgery in Locally Advanced Dermatofibrosarcoma Protuberans. Cancers, 2021, 13, 2224.	3.7	8
15	Systemic Treatment Initiation in Classical and Endemic Kaposiâ€™s Sarcoma: Risk Factors and Global Multi-State Modelling in a Monocentric Cohort Study. Cancers, 2021, 13, 2519.	3.7	10
16	Turning tumors from cold to inflamed to improve immunotherapy response. Cancer Treatment Reviews, 2021, 101, 102227.	7.7	42
17	Outcome of pretransplant melanoma after solid organ transplantation: an observational study. Transplant International, 2021, 34, 2154-2165.	1.6	0
18	Immune Checkpoint Inhibitors in Transplantationâ€“A Case Series and Comprehensive Review of Current Knowledge. Transplantation, 2021, 105, 67-78.	1.0	21

#	ARTICLE	IF	CITATIONS
19	Acquired generalized lipodystrophy under immune checkpoint inhibition. <i>British Journal of Dermatology</i> , 2020, 182, 477-480.	1.5	29
20	Clinical significance of BRAF/NRAS concurrent mutations in a clinicâ€based metastatic melanoma cohort. <i>British Journal of Dermatology</i> , 2020, 182, 1281-1283.	1.5	3
21	Intermittent Versus Continuous Dosing of MAPK Inhibitors in the Treatment of BRAF-Mutated Melanoma. <i>Translational Oncology</i> , 2020, 13, 275-286.	3.7	13
22	Targeted therapies in melanoma beyond BRAF: targeting NRAS-mutated and KIT-mutated melanoma. <i>Current Opinion in Oncology</i> , 2020, 32, 79-84.	2.4	25
23	Impact of New Systemic Treatment and Radiotherapy in Melanoma Patients with Leptomeningeal Metastases. <i>Cancers</i> , 2020, 12, 2635.	3.7	5
24	Increased risk of brain metastases among patients with melanoma and PROM2 expression in metastatic lymph nodes. <i>Clinical and Translational Medicine</i> , 2020, 10, e198.	4.0	3
25	A Melanoma-Tailored Next-Generation Sequencing Panel Coupled with a Comprehensive Analysis to Improve Routine Melanoma Genotyping. <i>Targeted Oncology</i> , 2020, 15, 759-771.	3.6	2
26	Combined Therapy with Anti-PD1 and BRAF and/or MEK Inhibitor for Advanced Melanoma: A Multicenter Cohort Study. <i>Cancers</i> , 2020, 12, 1666.	3.7	17
27	Deep cutaneous fungal infections in solid-organ transplant recipients. <i>Journal of the American Academy of Dermatology</i> , 2020, 83, 455-462.	1.2	11
28	FGF2 Induces Resistance to Nilotinib through MAPK Pathway Activation in KIT Mutated Melanoma. <i>Cancers</i> , 2020, 12, 1062.	3.7	7
29	Haemophagocytic lymphohistiocytosis associated with immune checkpoint inhibitors: a descriptive case study and literature review. <i>British Journal of Haematology</i> , 2020, 189, 985-992.	2.5	27
30	Standardized Patients or Conventional Lecture for Teaching Communication Skills to Undergraduate Medical Students: A Randomized Controlled Study. <i>Psychiatry Investigation</i> , 2020, 17, 299-305.	1.6	12
31	Long-lasting, irreversible and late-onset immune-related adverse events (irAEs) from immune checkpoint inhibitors (ICIs): A real-world data analysis.. <i>Journal of Clinical Oncology</i> , 2020, 38, e15095-e15095.	1.6	3
32	A process mining approach to real-world advanced melanoma treatments.. <i>Journal of Clinical Oncology</i> , 2020, 38, e22040-e22040.	1.6	1
33	Eosinophilic granulomatosis with polyangiitis (Churg-Strauss) induced by immune checkpoint inhibitors. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, e82-e82.	0.9	30
34	Atypical BRAF and NRAS Mutations in Mucosal Melanoma. <i>Cancers</i> , 2019, 11, 1133.	3.7	47
35	Cochleovestibular toxicity induced by immune checkpoint inhibition: a case series. <i>European Journal of Cancer</i> , 2019, 117, 116-118.	2.8	12
36	Recurrence of Immune-Mediated Colitis Upon Immune Checkpoint Inhibitor Resumption: Does Time Matter?. <i>Journal of Clinical Oncology</i> , 2019, 37, 3563-3564.	1.6	7

#	ARTICLE	IF	CITATIONS
37	Malignant, benign conventional and regulatory T immune compartments in 36 patients treated with mogamulizumab for advanced CTCL. <i>European Journal of Cancer</i> , 2019, 119, S4-S5.	2.8	0
38	Baseline Genomic Features in BRAFV600-Mutated Metastatic Melanoma Patients Treated with BRAF Inhibitor + MEK Inhibitor in Routine Care. <i>Cancers</i> , 2019, 11, 1203.	3.7	10
39	Long-term outcome of neoadjuvant tyrosine kinase inhibitors (TKI) in locally advanced dermatofibrosarcoma protuberans (DFSP). <i>Annals of Oncology</i> , 2019, 30, v698.	1.2	0
40	Efficacy and safety of brentuximab vedotin plus bendamustine in advanced-stage primary cutaneous T-cell lymphomas. <i>British Journal of Dermatology</i> , 2019, 181, 1315-1317.	1.5	14
41	Management of Kaposi sarcoma after solid organ transplantation: A European retrospective study. <i>Journal of the American Academy of Dermatology</i> , 2019, 81, 448-455.	1.2	31
42	Rechallenge of immune checkpoint inhibitor after pembrolizumab-induced myasthenia gravis. <i>European Journal of Cancer</i> , 2019, 113, 72-74.	2.8	13
43	Usefulness of the "two-step method" of digital follow-up for early-stage melanoma detection in high-risk French patients: a retrospective 4-year study. <i>British Journal of Dermatology</i> , 2019, 181, 415-416.	1.5	7
44	Severe gastrointestinal toxicity of MEK inhibitors. <i>Melanoma Research</i> , 2019, 29, 556-559.	1.2	13
45	Kaposi Sarcoma in HIV-positive Solid-Organ Transplant Recipients: A French Multicentric National Study and Literature Review. <i>Transplantation</i> , 2019, 103, e22-e28.	1.0	13
46	Refractory hypotension with fever revealing checkpoint inhibitor-induced hypophysitis. <i>Melanoma Research</i> , 2019, 29, 205-207.	1.2	2
47	Checkpoint inhibitor treatment induces an increase in HbA1c in nondiabetic patients. <i>Melanoma Research</i> , 2019, 29, 328-332.	1.2	6
48	Management of immune-related adverse events resulting from immune checkpoint blockade. <i>Expert Review of Anticancer Therapy</i> , 2019, 19, 209-222.	2.4	20
49	Immune checkpoint inhibitor rechallenge in patients with immune-related myositis. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, e129-e129.	0.9	30
50	Phase I-II open label multicenter study of PD0332991 in <i>BRAF</i> ^{V600mut} metastatic melanoma patients harboring <i>CDKN2A</i> loss and RB1 expression and treated with vemurafenib.. <i>Journal of Clinical Oncology</i> , 2019, 37, 9545-9545.	1.6	3
51	A targeted genomic alteration analysis predicts survival of melanoma patients under BRAF inhibitors. <i>Oncotarget</i> , 2019, 10, 1669-1687.	1.8	12
52	PD-1 blockade with nivolumab in endemic Kaposi sarcoma. <i>Annals of Oncology</i> , 2018, 29, 1067-1069.	1.2	34
53	STAT3 Mediates Nilotinib Response in KIT-Altered Melanoma: A Phase II Multicenter Trial of the French Skin Cancer Network. <i>Journal of Investigative Dermatology</i> , 2018, 138, 58-67.	0.7	47
54	Enteritis without colitis in patients treated with immune checkpoint inhibitors: a tricky diagnosis. <i>Melanoma Research</i> , 2018, 28, 483-484.	1.2	9

#	ARTICLE	IF	CITATIONS
55	Letter to the Editor: Could Immunogenicity of Kaposi Sarcoma Be More Linked to Viral Antigens Than to the Tumor Mutational Burden?. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2018, 16, 1418-1419.	4.9	4
56	Nivolumab-induced alopecia areata: A reversible factor of good prognosis?. <i>JAAD Case Reports</i> , 2018, 4, 761-765.	0.8	21
57	A multicenter phase II study of pazopanib in patients with unresectable or recurrent dermatofibrosarcoma protuberans (DFSP).. <i>Journal of Clinical Oncology</i> , 2018, 36, 11557-11557.	1.6	4
58	PDE4D promotes FAK-mediated cell invasion in BRAF-mutated melanoma. <i>Oncogene</i> , 2017, 36, 3252-3262.	5.9	25
59	Transient pituitary ACTH-dependent Cushing syndrome caused by an immune checkpoint inhibitor combination. <i>Melanoma Research</i> , 2017, 27, 649-652.	1.2	33
60	Survival After Fulminant Myocarditis Induced by Immune-Checkpoint Inhibitors. <i>Annals of Internal Medicine</i> , 2017, 167, 683.	3.9	60
61	Keratinocyte Dystrophy as a Marker of Low-Dose Methotrexate-Induced Skin Toxicity: Comment on the Clinical Image by MÄnch et al. <i>Arthritis and Rheumatology</i> , 2016, 68, 1790-1791.	5.6	2
62	Hypoxia and MITF regulate KIT oncogenic properties in melanocytes. <i>Oncogene</i> , 2016, 35, 5070-5077.	5.9	5
63	Validation of a preclinical model for assessment of drug efficacy in melanoma. <i>Oncotarget</i> , 2016, 7, 13069-13081.	1.8	12
64	<sc>EMMPRIN</sc> regulates <i>Î²1</i> integrin-mediated adhesion through Kindlin-3 in human melanoma cells. <i>Experimental Dermatology</i> , 2015, 24, 443-448.	2.9	10
65	The Ipilimumab Lesson in Melanoma: Achieving Long-Term Survival. <i>Seminars in Oncology</i> , 2015, 42, 387-401.	2.2	24
66	Low-dose methotrexate-induced skin toxicity: Keratinocyte dystrophy as a histologic marker. <i>Journal of the American Academy of Dermatology</i> , 2015, 73, 484-490.	1.2	39
67	Effect of extracellular matrix metalloproteinase inducer emmprin on α 1 integrin-mediated adhesion through a new partner, the kindlin-3, in human melanoma cells.. <i>Journal of Clinical Oncology</i> , 2014, 32, e22011-e22011.	1.6	0
68	Specific lymph node involvement in scleromyxedema: a new diagnostic entity for hypermetabolic lymphadenopathy. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2013, 462, 679-683.	2.8	6
69	Experience in daily practice with ipilimumab for the treatment of patients with metastatic melanoma: an early increase in lymphocyte and eosinophil counts is associated with improved survival. <i>Annals of Oncology</i> , 2013, 24, 1697-1703.	1.2	280
70	Hemophilia A Induced by Ipilimumab. <i>New England Journal of Medicine</i> , 2011, 365, 1747-1748.	27.0	93